The new, multinational iReceptor Plus Consortium will develop a platform for sharing of AIRR-seq data to advance immunotherapy and precision medicine.
The researchers hope the datasets from their study can help to explain the effects of disease-associated variants on specific cell types of the immune system.
OMI researchers will apply and validate 1CellBio's inDrop system to generate predictive data for patients with undiagnosed immune dysfunction conditions.
Using the publicly available ImmPort database, researchers standardized and analyzed immune-related data for more than 10,300 healthy individuals.
The researchers characterized how gene therapy affects the immune cell repertoires and microbiomes of X-linked severe combined immunodeficiency patients.
The company shared early evidence of the potential of its approach to improve newborn screening for immune disorders, and to offer new tools for other areas like HIV monitoring.
Using the method, the researchers predicted the effects of over 140 million mutations in different tissues and identified mutations possibly associated with increased risk of several immune diseases.
Researchers provided genetic diagnoses for about 68 percent of their primary antibody deficiency cohort, which altered clinical management in about half of them.
Using a mass cytometry method called EpiTOF, researchers profiled histone modifications and variants in a range of immune cell types across individuals of different ages.
In analyses of multiple traits and diseases, investigators uncovered loss-of-function or truncating changes with apparent protective effects.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.